Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Guidelines for primary central nervous system lymphoma

Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

Key clinical point: The British Society of Haematology has issued the first new guidelines for diagnosis and treatment of primary central nervous system lymphoma in more than a decade.

Major finding: Treatment for PCNSL should start within 2 weeks of diagnosis and should be based on a patient’s physiological fitness, not their age.

Study details: A systematic review of published literature from Jan. 1, 2007 to May 29, 2017.

Disclosures: The PCNSL guideline writing process was sponsored by the British Society for Haematology, and some coauthors, including the lead author, disclosed receiving fees from pharmaceutical manufacturers Adienne or F. Hoffman-La Roche.

Read the article here.

Citation:

Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661.

This Week's Must Reads

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

Must Reads in Aggressive Lymphomas

'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4

Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6